New York · Nonprofit
LUPUS RESEARCH ALLIANCE INC
LUPUS RESEARCH ALLIANCE INC (New York) receives grants from 278 organizations whose IRS filings report $77,291,135 to it, the largest being THE BLOOMBERG FAMILY FOUNDATION INC ($39,800,000). 136 of them have funded it in more than one year.
- Revenue FY2025
- $24M
- Funders on record
- 278
- Grants received
- $77M
- Net assets
- $49M
What Lupus Research Alliance Inc does
Mission
Putting people with lupus at the center of all we do, the lupus research alliance drives the discovery & development of next generation lupus diagnostics and curative treatments through innovative research & collaborations.
As stated on its FY2025 Form 990.
Programs
The lupus research alliance (lra), the largest non-governmental, private funder of lupus research worldwide. The organization's research committee of the board of directors and scientific advisory board includes top scientific experts, and key lay members of the lra's board of directors, who work with staff to strategically guide and drive the research funding agenda. The lra funds innovative research that spans the spectrum from foundational to clinical research. The lra has invested nearly $228 million in lupus research grants including 675+ research grants. In 2025 over $12 million was awarded in grants for over 31 highly innovative projects with the potential to improve treatment as well as understand the causes of lupus and thus lead to a cure. Below is a summary of research grants and programs funded by the lra in 2025: 6 lupus innovation award grants were awarded totaling over $2 million over two years, this program supports pioneering, high-risk, high-reward projects addressing major challenges in lupus research. Early-stage investigators are given special consideration during the review process and are eligible for a third year of funding; 7 empowering lupus research…
$15,426,770 spentof which $12,958,702 as grants47% of program spendingThe lupus research alliance (lra) advanced its scientific mission in 2025 by strengthening its research strategy, expanding operational grantmaking activities, and advancing collaborative initiatives designed to accelerate progress in lupus diagnosis, treatment, and clinical trial readiness.in 2025, lra implemented the second year of its 2024-2028 research strategy. As part of this work, lra renewed the common mechanisms in autoimmune diseases program and advanced planning for biomarker and data strategies intended to support more precise, efficient, and collaborative lupus research.lra's grantmaking programs, including the global team science award, empowering research program, lupus innovation award, translational bridge award, and mechanistic clinical trial award, continued to support innovative and translational lupus research. During 2025, lra also released multiple requests for applications through the global team science award and continued the administrative supplement training program to help strengthen the lupus research workforce. To increase awareness of its scientific programs and research findings, lra presented work at major scientific meetings and convened its…
$17,084,288 spentof which $3,052,329 as grants$2,057,382 earned by the program52% of program spendingThe lupus research alliance (lra)'s advocacy efforts focus on educating congress about lupus and urging congress and the administration to provide the funds and support needed to advance lupus research that can lead to better treatments and, ultimately, a cure. The top goals of the lupus research alliance public policy program focus mainly on funding for lupus research that will lead to better treatments for people living with lupus. Goals include: increasing federal funding for lupus research at the national institutes of health (nih), and specifically the national institute for allergy & infectious disease (niaid), and the national institute for arthritis & musculoskeletal disorders (niams). Additionally, the lra advocates for lupus research through the department of defense (dod) congressionally directed medical research programs (cdmrp); supporting the lupus accelerating breakthroughs consortium (lupus abc), the lra's partnership with the u.s. Food and drug administration (fda); and ensuring the patient voice is incorporated in the drug development process. Volunteer advocates across the country help amplify these outreach efforts.through the lra's ongoing public policy…
$645,427 spentof which $40,305 as grants2% of program spending
The 3 programs described on its FY2025 Form 990, listed largest first by expense. Program spending in total: $33,156,485.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2019 to 2020, from $71M to $103M (+45%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
Government-grant reliance: 2021 3% · 2022 1% · 2023 1%. Grants only. Government contracts and fees sit inside program revenue.
51% of LUPUS RESEARCH ALLIANCE INC’s revenue is contributions — more reliant on donations than three-quarters of its peers (7% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 7 of the last 9 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Albert T Roy
CEO and president
Board chair
Ira Akselrad
Chair
As listed on its FY2025 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 49 funders to 101 funders, grant income rose $5.1M → $13M.
40 of 278 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 31% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of LUPUS RESEARCH ALLIANCE INC’s funders (the co-funder graph). Top 30 of 278 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
LUPUS RESEARCH ALLIANCE INC leans on a few funders — its largest provides 51% of grant income and the top three 72%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
34% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund LUPUS RESEARCH ALLIANCE INC.
Largest funder’s share by year: 2017 79% · 2018 66% · 2019 50% · 2020 65% · 2021 81% · 2022 24% · 2023 74% — diversifying over time.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
35% of LUPUS RESEARCH ALLIANCE INC's funders are still giving 3 years after their first grant; 49% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
95% of LUPUS RESEARCH ALLIANCE INC's grant income comes from New York funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $24M arriving through sponsors registered in 19 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
LUPUS RESEARCH ALLIANCE INC's funding base is broadening — from 49 funders to 101 as grant income climbed.
this organization peer median middle 50% of peers· 2,969 health nonprofits $10M–$100M, FY2025
Organizations like LUPUS RESEARCH ALLIANCE INC
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In New York
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
79% of spending goes to programs.
Governance
Public support
56%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Footprint & structure
Files a return copy in 37 states
Part of a family of 2 related entities
- Lupus Therapeutics LLC · disregarded
- Lupus Ventures LLC · disregarded
Screen this organization
A dated, signed PDF of the compliance screen for LUPUS RESEARCH ALLIANCE INC: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds LUPUS RESEARCH ALLIANCE INC?
- LUPUS RESEARCH ALLIANCE INC (New York) receives grants from 278 organizations whose IRS filings report $77,291,135 to it, the largest being THE BLOOMBERG FAMILY FOUNDATION INC ($39,800,000). 136 of them have funded it in more than one year.
- How many funders does LUPUS RESEARCH ALLIANCE INC have?
- IRS filings report 278 organizations giving $77,291,135 in grants to LUPUS RESEARCH ALLIANCE INC, 136 of which have funded it in more than one year.
- Who is the largest funder of LUPUS RESEARCH ALLIANCE INC?
- THE BLOOMBERG FAMILY FOUNDATION INC is the largest funder on record, with $39,800,000 in grants. The full list of funders is on this page.
- How can an organization like LUPUS RESEARCH ALLIANCE INC find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in New York. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2025 (financials across 2017–2025), and the filings of 278 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 22, 2026. What this page cannot tell you · view filing